CLASS III Drug recall · Reported 7 Oct 2015 · FDA Enforcement Report

Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg recalled

Apotex is recalling Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg, distributed nationwide in the US. The recall was initiated on 21 Jul 2015 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot #: KP2621, Exp 8/2015
Quantity recalled2,075 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D1834-2015
FDA event ID
72118
Recalling firm
Apotex, Toronto, Ontario
Classification
Class III
Status
Terminated
Recall initiated
21 Jul 2015
FDA classified
30 Sep 2015
Reported
7 Oct 2015
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

21 Jul 2015Recall initiated by company
30 Sep 2015Classified by FDA+71 days
7 Oct 2015Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specification: One lot of product did not meet the first stage dissolution specification limits.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg, 500-count bottles, Rx Only, Apotex Corp. Manufactured by Apotex Research Private Limited, Bangalore, Karnataka 560 099, India; Manufactured for: Apotex Corp., Weston, FL 33326. NDC 60505-2742-5.

Where it was distributed

Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg recalled?

Yes. Apotex recalled Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg on 21 Jul 2015. The recall is Class III and its status is Terminated. Recall number D1834-2015.

Why was it recalled?

Failed Dissolution Specification: One lot of product did not meet the first stage dissolution specification limits.

Which lots are affected?

Lot #: KP2621, Exp 8/2015

Where was it sold?

Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Apotex

All 75
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPaxil CR, Paroxetine, Extended-Release Tablets, 5mg recalled by ApotexApotexPotency & AssayNationwide
DrugCLASS IIDesmopressin Nasal Spray, USP, 10 mcg/ bottle (50 doses) recalledApotexOtherNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 2%/0.5%* recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide

Other Verapamil recalls

All 8